Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report

Bruce Shiramizu; Stanton Goldman; Lynette Smith; Melissa Agsalda-Garcia; Paul Galardy; Sherrie L. Perkins; J. Kimble Frazer; Warren Sanger; James R. Anderson; Thomas G. Gross; Howard Weinstein; Lauren Harrison; Matthew J. Barth; Lara Mussolin; Mitchell S. Cairo

doi:10.1111/bjh.13443

Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report

Bruce Shiramizu, Stanton Goldman, Lynette Smith, Melissa Agsalda-Garcia, Paul Galardy, Sherrie L. Perkins, J. Kimble Frazer, Warren Sanger, James R. Anderson, Thomas G. Gross, Howard Weinstein, Lauren Harrison, Matthew J. Barth, Lara Mussolin, Mitchell S. Cairo

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

Patient-specific primers from 10 children/adolescents with Burkitt leukaemia (BL) ± central nervous system disease who were treated with French-British-American/Lymphome Malins de Burkitt 96 C1 plus rituximab were developed from diagnostic blood/bone marrow. Minimal residual disease (MRD) was assessed by real-time polymerase chain reaction at the end of induction (EOI) and consolidation (EOC). Seventy per cent (7/10) and 71% (5/7) were MRD-positive at EOI and EOC, respectively, with no disease recurrences. MRD after induction and consolidation did not predict relapse and subsequent therapy appeared to eliminate MRD. Thus, assessing MRD at a later time point is warranted in future trials to determine its clinical significance.

Original language	English (US)
Pages (from-to)	367-371
Number of pages	5
Journal	British Journal of Haematology
Volume	170
Issue number	3
DOIs	https://doi.org/10.1111/bjh.13443
State	Published - 2015

Keywords

central nervous system
children
leukaemia

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/bjh.13443

Cite this

Shiramizu, B., Goldman, S., Smith, L., Agsalda-Garcia, M., Galardy, P., Perkins, S. L., Frazer, J. K., Sanger, W., Anderson, J. R., Gross, T. G., Weinstein, H., Harrison, L., Barth, M. J., Mussolin, L., & Cairo, M. S. (2015). Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report. British Journal of Haematology, 170(3), 367-371. https://doi.org/10.1111/bjh.13443

Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report. / Shiramizu, Bruce; Goldman, Stanton; Smith, Lynette et al.
In: British Journal of Haematology, Vol. 170, No. 3, 2015, p. 367-371.

Research output: Contribution to journal › Article › peer-review

Shiramizu, B, Goldman, S, Smith, L, Agsalda-Garcia, M, Galardy, P, Perkins, SL, Frazer, JK, Sanger, W, Anderson, JR, Gross, TG, Weinstein, H, Harrison, L, Barth, MJ, Mussolin, L & Cairo, MS 2015, 'Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report', British Journal of Haematology, vol. 170, no. 3, pp. 367-371. https://doi.org/10.1111/bjh.13443

@article{5699597908b94195b0a616a5c7b0e001,

title = "Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report",

abstract = "Patient-specific primers from 10 children/adolescents with Burkitt leukaemia (BL) ± central nervous system disease who were treated with French-British-American/Lymphome Malins de Burkitt 96 C1 plus rituximab were developed from diagnostic blood/bone marrow. Minimal residual disease (MRD) was assessed by real-time polymerase chain reaction at the end of induction (EOI) and consolidation (EOC). Seventy per cent (7/10) and 71% (5/7) were MRD-positive at EOI and EOC, respectively, with no disease recurrences. MRD after induction and consolidation did not predict relapse and subsequent therapy appeared to eliminate MRD. Thus, assessing MRD at a later time point is warranted in future trials to determine its clinical significance.",

keywords = "central nervous system, children, leukaemia",

author = "Bruce Shiramizu and Stanton Goldman and Lynette Smith and Melissa Agsalda-Garcia and Paul Galardy and Perkins, {Sherrie L.} and Frazer, {J. Kimble} and Warren Sanger and Anderson, {James R.} and Gross, {Thomas G.} and Howard Weinstein and Lauren Harrison and Barth, {Matthew J.} and Lara Mussolin and Cairo, {Mitchell S.}",

note = "Publisher Copyright: {\textcopyright} 2015 John Wiley & Sons Ltd",

year = "2015",

doi = "10.1111/bjh.13443",

language = "English (US)",

volume = "170",

pages = "367--371",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia

T2 - a Children's Oncology Group Pilot Study Report

AU - Shiramizu, Bruce

AU - Goldman, Stanton

AU - Smith, Lynette

AU - Agsalda-Garcia, Melissa

AU - Galardy, Paul

AU - Perkins, Sherrie L.

AU - Frazer, J. Kimble

AU - Sanger, Warren

AU - Anderson, James R.

AU - Gross, Thomas G.

AU - Weinstein, Howard

AU - Harrison, Lauren

AU - Barth, Matthew J.

AU - Mussolin, Lara

AU - Cairo, Mitchell S.

PY - 2015

Y1 - 2015

N2 - Patient-specific primers from 10 children/adolescents with Burkitt leukaemia (BL) ± central nervous system disease who were treated with French-British-American/Lymphome Malins de Burkitt 96 C1 plus rituximab were developed from diagnostic blood/bone marrow. Minimal residual disease (MRD) was assessed by real-time polymerase chain reaction at the end of induction (EOI) and consolidation (EOC). Seventy per cent (7/10) and 71% (5/7) were MRD-positive at EOI and EOC, respectively, with no disease recurrences. MRD after induction and consolidation did not predict relapse and subsequent therapy appeared to eliminate MRD. Thus, assessing MRD at a later time point is warranted in future trials to determine its clinical significance.

AB - Patient-specific primers from 10 children/adolescents with Burkitt leukaemia (BL) ± central nervous system disease who were treated with French-British-American/Lymphome Malins de Burkitt 96 C1 plus rituximab were developed from diagnostic blood/bone marrow. Minimal residual disease (MRD) was assessed by real-time polymerase chain reaction at the end of induction (EOI) and consolidation (EOC). Seventy per cent (7/10) and 71% (5/7) were MRD-positive at EOI and EOC, respectively, with no disease recurrences. MRD after induction and consolidation did not predict relapse and subsequent therapy appeared to eliminate MRD. Thus, assessing MRD at a later time point is warranted in future trials to determine its clinical significance.

KW - central nervous system

KW - children

KW - leukaemia

UR - http://www.scopus.com/inward/record.url?scp=84964696036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964696036&partnerID=8YFLogxK

U2 - 10.1111/bjh.13443

DO - 10.1111/bjh.13443

M3 - Article

C2 - 25858645

AN - SCOPUS:84964696036

SN - 0007-1048

VL - 170

SP - 367

EP - 371

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 3

ER -

Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this